Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Servier and Vernalis form new cancer alliance

Servier and Vernalis form new cancer alliance

18th January 2012

Servier has entered into a new collaboration with Vernalis focusing on the discovery of new treatments against an unspecified oncology target.

The new three-year arrangement will utilise Vernalis' proprietary fragment and structure-based drug discovery platform, with Servier to pay undisclosed fees and royalties depending on the success of the research.

It is the third collaborative agreement between the two companies in the field of oncology, allowing Servier to continue to take advantage of technology that has also been utilised by companies such as Biogen Idec, GlaxoSmithKline and Novartis.

Vernalis chief executive officer Ian Garland expressed positivity about the prospect of maintaining a working relationship with Servier that has now lasted for four years.

Dr Bernard Marchand, head of Servier Research, added: "One of Servier's strategic objectives is to accelerate our discovery process for innovative therapies in cancer, and Vernalis technology and scientists are offering a very valuable complement to our internal activities."

This comes after Servier agreed another cancer collaboration with BioInvent International earlier this month.ADNFCR-8000103-ID-801267675-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.